4T1-bearing mice responded with significant tumor regression and tumor elimination to our therapeutic combination regimen consisting of intratumoral delivery of high-mobility group nucleosome binding protein 1 (HMGN1), TLR2/6 ligand fibroblast-stimulating lipopeptide (FSL-1), TLR7/8 agonist (R848/resiquimod), and CTLA-4 blockade (termed TheraVacPlus). Here, HMGN1 is linked to neoplasm.